Oral presentation gives more details from the Phase II data where topline results were released on June 29, 2023. Investigators for the Phase II trial concluded that: The majority of the glioma patients displayed uPAR-positive tumors High uPAR expression is significantly correlated with a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.